Mutations in the U2 snRNA gene RNU2-2P cause a severe neurodevelopmental disorder with prominent epilepsy

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was made possible through access to data in the NGRL, which is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The NGRL holds data provided by patients and collected by the NHS as part of their care and data collected as part of their participation in research. The NGRL is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centers, NHS Trusts and staff for their contribution. We thank the National Institute for Health and Care Research, NHS Blood and Transplant, and Health Data Research UK as part of the Digital Innovation Hub Programme. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. K.F. was supported by Katholieke Universiteit (KU) Leuven Special Research Fund (BOF) (C14/19/096 and C14/23/121), Research Foundation - Flanders (G072921N) and NIH award R01HL161365. K.D.W. was supported by the Belgian American Education Foundation and NIH award R01HL161365. A.M. was supported by NIH award R01HL161365. D.G., and E.T. were supported by NIH awards R01HL161365 and R03HD111492 and E.T. was further supported by the Lowy Foundation USA.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Participants of the 100,000 Genomes Project, the 100,000 Genomes Project Pilot Project and the Genomic Medicine Service were enrolled to the National Genomic Research Library (NGRL) under a protocol approved by the East of England-Cambridge Central Research Ethics Committee (ref: 20/EE/0035). We obtained written informed consent to publish additional clinical data from a subset of the affected cases in the NGRL following local best practices. NIHR BioResource participants were enrolled under a protocol approved by the East of England Cambridge South Research Ethics Committee (ref. 13/EE/0325).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes